Skip Navigation



eCAM Advance Access published online on November 11, 2009

eCAM, doi:10.1093/ecam/nep174
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Modarai, M.
Right arrow Articles by Kortenkamp, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Modarai, M.
Right arrow Articles by Kortenkamp, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author(s) 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Safety of Herbal Medicinal Products: Echinacea and Selected Alkylamides do not Induce CYP3A4 mRNA Expression

Maryam Modarai1,2, Elisabete Silva2, Andy Suter3, Michael Heinrich1 and Andreas Kortenkamp2

1Centre for Pharmacognosy and Phytotherapy, 2Centre for Toxicology, The School of Pharmacy, University of London, London, WC1N 1AX, UK and 3Bioforce AG, CH-9325 Roggwil, Switzerland

A major safety concern with the use of herbal medicinal products (HMP) is their interactions with conventional medicines, which are often mediated via the cytochrome P450 (CYP) system. Echinacea is a widely used over-the-counter HMP, with proven immunomodulatory properties. Its increasing use makes research into its safety an urgent concern. Previously, we showed that Echinacea extracts and its alkylamides (thought to be important for Echinacea's immunomodulatory activity) mildly inhibit the enzymatic activity of the main drug metabolising CYP isoforms, but to this date, there is insufficient work on its ability to alter CYP expression levels. We now report for the first time the effect of a commercial Echinacea extract (Echinaforce®) and four Echinacea alkylamides on the transcription of the major drug metabolizing enzyme CYP3A4. HepG2 cells were exposed for 96 h to clinically relevant concentrations of Echinaforce (22, 11.6 and 1.16 µg ml–1) or the alkylamides (1.62 and 44 nM). CYP3A4 mRNA levels were quantified using real-time reverse transcription polymerase chain reaction (RT-PCR). Neither Echinaforce® nor the alkylamides produced any significant changes in the steady-state CYP3A4 mRNA levels, under these conditions. In contrast, treatment with 50 µM rifampicin resulted in a 3.8-fold up-regulation over the vehicle control. We conclude that Echinaforce® is unlikely to affect CYP3A4 transcriptional levels, even at concentrations which can inhibit the enzymatic activity of CYP3A4. Overall, our data provides further evidence for the lack of interactions between Echinacea and conventional drugs.

Keywords: Cytochrome P450 enzymes – cytochrome P450 induction – drug interactions – Echinacea purpurea – herb – real-time reverse transcription polymerase chain reaction


For reprints and all correspondence: Prof. Andreas Kortenkamp, Centre for Toxicology, The School of Pharmacy, University of London, 29/39 Brunswick Square, London, WC1N 1AX, UK. Tel/Fax: +44-207-753-5908; E-mail: andreas.kortenkamp{at}pharmacy.ac.uk

Received May 20, 2009; accepted October 2, 2009


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.